Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd and Merck KGaA are Dominating in the North America Kirsten Rat Sarcoma (KRAS) Market in 2020

North America Kirsten Rat Sarcoma (KRAS) Market is expected to grow with the CAGR of 11.8% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below:

Access Full Report @ https://www.databridgemarketresearch.com/reports/north-america-kristen-rat-sarcoma-kras-market

North America Kirsten rat sarcoma (KRAS) market is a highly consolidated market which includes specific number of key players as well as local players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in Kirsten rat sarcoma (KRAS) market are introducing strong range of product portfolio. This has helped the companies to maximize the sales with enhanced product portfolio. For instance, in October 2018, Illumina, Inc. had launched the True Sight Oncology 500. The liquid biopsy panel is a comprehensive pan-cancer assay which has been designed to identify and detect known and upcoming tumor biomarkers. The panel launched by the company were used for molecular testing of biomarkers in lung cancer, being implemented for precision oncology and strengthened the oncology portfolio. It demonstrated a positive growth in the market. The company's introduction of this new product has boosted its credibility and market demand.

Thermo Fisher Scientific Inc. is the dominating player in the North America Kirsten rat sarcoma (KRAS) market. The other key players existing in the Kirsten rat sarcoma (KRAS) market includes F. Hoffmann-La Roche Ltd, QIAGEN, Agilent Technologies, Inc., Merck KGaA, MIRADX, Illumina, Inc., Abbott, Agena Bioscience, Inc., Takara Bio Inc., Biocartis, EntroGen, Inc., ViennaLab Diagnostics GmbH, Sysmex Inostics, Proteintech Group, Inc., CENTOGENE N.V., Amoy Diagnostics Co., Ltd., DiaCarta among others.

North America Kristen Rat Sarcoma (KRAS) Market Thermo Fisher Scientific Inc.:

Thermo Fisher Scientific Inc. is headquartered in Massachusetts, U.S. and was founded in 2006. The company focuses to allow their customers to make the world healthier, cleaner and safer. The company deals in multiple business segments such as analytical instruments, life sciences solutions, specialty diagnostics and laboratory products & services among which specialty diagnostics is the market focused segment. The company provides various products under categories such as laboratory supplies, laboratory equipment, laboratory instruments, clinical & diagnostics, chromatography & mass spectrometry, cell culture, protein and cell analysis, molecular biology & nucleic acid analysis and sequence-specific nucleic acid products out of which molecular biology & nucleic acid analysis and protein and cell analysis are the market focused categories.

For instance,

  • In October 2020, Thermo Fischer Scientific Inc. had announced to extend its collaboration with Symphogen to provide innovative cancer treatments through optimization of protein characterization and quality monitoring mass spectrometry workflows. The companies can provide the biopharmaceutical industry with compliance to ready mass spectrometer solutions to boost the drug delivery. It would deliver a positive growth in the market.     

The company has presence in Americas, Europe, Asia-Pacific and Middle East and Africa. The company has various subsidiaries that are Patheon (Netherlands), Cole Parmer (U.S.), REMEL INC (U.S.), Acros Organics B.V.B.A. (U.S.), FEI Company (U.S.) among others.

F. Hoffman La Roche Ltd:

F. Hoffman La Roche Ltd is headquartered in Basel, Switzerland and was founded in 1896. The company is focused on development of innovative medicines and diagnostics tests that help patients live longer and better lives. The company deals in multiple business segments such as pharmaceuticals, diagnostics and corporate among which diagnostics is the market focused segment. The company provides various products under categories such as blood safety, clinical chemistry & immunochemistry, companion diagnostics, custom biotech, diabetes care, lab automation & software solution, molecular diagnostics, point of care and tissue diagnostics out of which molecular diagnostics is the market focused category.

For instance,

  • In November 2015, F. Hoffmann-La Roche Ltd announced that they had expanded molecular diagnostic assays by Cobas 4800. This system will improve the efficiency and flexibility that allows laboratories to deliver results for rapid clinical decisions. This has increase the demand for the product in the recent past and is expected to increase in the forecasted period.

The company has wide global presence across the world in Americas, Europe, Asia-Pacific and Middle East and Africa. The company has various subsidiaries that are Genentech (U.S.), Chugai Pharmaceutical Co. (Japan), ROCHE HOLDING (UK) LIMITED (U.K.), Roche (Philippines) Inc. (Philippines), Roche Chile Limitada (Chile) among others.